ARTEMIS-008 A Multicenter, Randomized, Open-label, Phase 3 Study of HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy
Latest Information Update: 21 Oct 2024
At a glance
- Drugs HS-20093 (Primary) ; Topotecan
- Indications Small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms ARTEMIS-008
- Sponsors Hansoh BioMedical R&D Company
Most Recent Events
- 16 Oct 2024 Status changed from not yet recruiting to recruiting.
- 18 Jul 2024 New trial record